Lpath to Present at Upcoming Roth Investor Conference

SAN DIEGO, March 4, 2014 /PRNewswire/ -- Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, today announced that Scott Pancoast, president and CEO, will be presenting at the 26^th Annual Roth Conference being held March 10 -12, 2014 in Laguna Niguel, Calif. Mr. Pancoast is scheduled to present on March 11, 2014 at 4:30 p.m. PST/7:30 p.m. EST. The presentation will be webcast live and will be available for replay on the Lpath, Inc. corporate website at www.Lpath.com.

About Lpath
San Diego-based Lpath, Inc. (NASDAQ: LPTN), an antibody-platform company, is the category leader in lipid-targeted therapeutics. The company's ImmuneY2™ drug-discovery engine has the unique ability to generate therapeutic antibodies that bind to and inhibit bioactive lipids that contribute to disease. With this platform, the company has developed four drug candidates, two of which—iSONEP for wet AMD and ASONEP for cancer—are currently being investigated in Phase 2 trials. The other candidates are an anti-LPA antibody, Lpathomab, currently in IND-enabling studies for neuropathic pain and neurotrauma, and an anti-leukotriene antibody, Altepan, which is being studied in models of respiratory disease. For more information, visit www.Lpath.com.

CONTACT:
Scott R. Pancoast
President and CEO
Lpath, Inc.
858-926-3200
[email protected]

INVESTOR CONTACT:
Westwicke Partners, LLC
Robert H. Uhl
Managing Director
858-356-5932
[email protected]

SOURCE Lpath, Inc.